Stay updated on ELVN-001 for CML Treatment Clinical Trial
Sign up to get notified when there's something new on the ELVN-001 for CML Treatment Clinical Trial page.

Latest updates to the ELVN-001 for CML Treatment Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to reflect an increase in the number of study locations from 42 to 46, with new recruiting sites added in Warsaw, Budapest, Leuven, and the Bronx, along with updated contact information for key personnel.SummaryDifference4%
- Check9 days agoChange DetectedThe page now includes a service alert regarding planned maintenance starting July 25th, indicating that most services will be unavailable for over 24 hours. The previous mention of an estimated last update has been removed.SummaryDifference2%
- Check16 days agoChange DetectedThe web page has been updated to reflect an increase in the number of study locations from 39 to 42, and it now includes new contact information for several recruiting sites in the UK, Hungary, and Belgium. Additionally, there are updates to the eligibility criteria for patients regarding treatment options for CML.SummaryDifference8%
- Check30 days agoChange DetectedThe page now indicates that the ClinicalTrials.gov data ingest is expected to be modernized in July 2025, with an increase in the number of study locations from 35 to 39. Additionally, several new contact details for recruiting sites in Poland, the Netherlands, Italy, and Belgium have been added.SummaryDifference4%
- Check37 days agoChange DetectedThe web page has been updated to a new version, v2.16.3, replacing the previous version v2.16.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has updated the number of study locations from 34 to 35 and added a new contact for a medical facility in Nowy Sącz, Poland.SummaryDifference2%
Stay in the know with updates to ELVN-001 for CML Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ELVN-001 for CML Treatment Clinical Trial page.